HUE041781T2 - Ellenanyagok klaudin-6-ot expresszáló rák kezelésére - Google Patents
Ellenanyagok klaudin-6-ot expresszáló rák kezeléséreInfo
- Publication number
- HUE041781T2 HUE041781T2 HUE15201110A HUE15201110A HUE041781T2 HU E041781 T2 HUE041781 T2 HU E041781T2 HU E15201110 A HUE15201110 A HU E15201110A HU E15201110 A HUE15201110 A HU E15201110A HU E041781 T2 HUE041781 T2 HU E041781T2
- Authority
- HU
- Hungary
- Prior art keywords
- antibodies
- treatment
- cancer expressing
- expressing claudin
- claudin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161486071P | 2011-05-13 | 2011-05-13 | |
| EP11004004 | 2011-05-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE041781T2 true HUE041781T2 (hu) | 2019-05-28 |
Family
ID=65681287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE15201110A HUE041781T2 (hu) | 2011-05-13 | 2012-04-20 | Ellenanyagok klaudin-6-ot expresszáló rák kezelésére |
Country Status (7)
| Country | Link |
|---|---|
| JP (2) | JP6748282B2 (hu) |
| KR (1) | KR102128027B1 (hu) |
| ES (1) | ES2703936T3 (hu) |
| HU (1) | HUE041781T2 (hu) |
| PT (1) | PT3026064T (hu) |
| SG (1) | SG10201911551RA (hu) |
| TR (1) | TR201821021T4 (hu) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0907237A2 (pt) * | 2008-01-11 | 2015-07-14 | Univ Tokyo | Anticorpo anti-cldn6 |
| NO2499161T3 (hu) * | 2009-11-11 | 2018-02-03 |
-
2012
- 2012-04-20 ES ES15201110T patent/ES2703936T3/es active Active
- 2012-04-20 PT PT15201110T patent/PT3026064T/pt unknown
- 2012-04-20 KR KR1020207002280A patent/KR102128027B1/ko active IP Right Grant
- 2012-04-20 HU HUE15201110A patent/HUE041781T2/hu unknown
- 2012-04-20 SG SG10201911551RA patent/SG10201911551RA/en unknown
- 2012-04-20 TR TR2018/21021T patent/TR201821021T4/tr unknown
-
2019
- 2019-12-19 JP JP2019228917A patent/JP6748282B2/ja active Active
-
2020
- 2020-08-06 JP JP2020133736A patent/JP7263294B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6748282B2 (ja) | 2020-08-26 |
| KR102128027B1 (ko) | 2020-06-30 |
| ES2703936T3 (es) | 2019-03-13 |
| TR201821021T4 (tr) | 2019-01-21 |
| KR20200014436A (ko) | 2020-02-10 |
| JP7263294B2 (ja) | 2023-04-24 |
| JP2020063282A (ja) | 2020-04-23 |
| PT3026064T (pt) | 2018-12-17 |
| JP2020186257A (ja) | 2020-11-19 |
| SG10201911551RA (en) | 2020-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20190014T1 (hr) | Antitijela za liječenje raka koji eksprimira claudin 6 | |
| IL282953A (en) | Substances for the treatment of cancer diseases that express claudin | |
| IL276434A (en) | Combined treatment involving antibodies against claudin 18.2 for the treatment of cancer | |
| IL279330A (en) | Combined treatment including antibodies against Claudin 18.2 for the treatment of cancer | |
| HK1254859A1 (zh) | 治療乳腺癌的方法 | |
| IL229254A0 (en) | Therapeutic antibodies | |
| PT2550296T (pt) | Anticorpos monoclonais para tratamento do cancro | |
| HK1185874A1 (zh) | 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺 | |
| IL228430A0 (en) | Cancer treatment | |
| ME02932B (me) | Kombinovana terapija koja uključuje antitela protiv klaudina 18.2 za lečenje kancera | |
| SG10201911551RA (en) | Antibodies for treatment of cancer expressing claudin 6 | |
| ZA201308992B (en) | Therapeutic antibodies | |
| GB201121783D0 (en) | Treatment of cancer |